Anfield Capital Management’s AbbVie ABBV Stock Holding History

Anfield Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$18.5K	Hold	85	–	–	0.01%	350
2025 Q4	$19.4K	Hold	85	–	–	0.01%	268
2025 Q3	$19.7K	Buy	85 +6	+8%	+$1.22K	0.01%	254
2025 Q2	$14.7K	Hold	79	–	–	﹤0.01%	247
2025 Q1	$16.6K	Hold	79	–	–	0.01%	202
2024 Q4	$14K	Hold	79	–	–	0.01%	205
2024 Q3	$15.6K	Hold	79	–	–	0.01%	188
2024 Q2	$13.6K	Buy	+79	New	+$13.1K	0.01%	163
2023 Q1	–	Sell	-1,076	Closed	-$174K	–	70
2022 Q4	$174K	Sell	1,076 -879	-45%	-$135K	0.09%	66
2022 Q3	$262K	Buy	1,955 +67	+4%	+$9.61K	0.12%	66
2022 Q2	$289K	Sell	1,888 -1,123	-37%	-$172K	0.13%	64
2022 Q1	$488K	Buy	+3,011	New	+$437K	0.18%	54
2021 Q3	–	Sell	-110	Closed	-$12K	–	127
2021 Q2	$12K	Buy	+110	New	+$12.4K	﹤0.01%	156
2020 Q1	–	Sell	-1,871	Closed	-$162K	–	102
2019 Q4	$162K	Buy	+1,871	New	+$155K	0.07%	133

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Anfield Capital Management's ABBV Position: Q1 2026 in Review

Anfield Capital Management held its AbbVie (ABBV) position steady in Q1 2026 at 85 shares worth $18.5K. The position accounts for 0.01% of the portfolio, ranked #350.

Anfield Capital Management first reported a position in ABBV in Q4 2019 and has held it in 14 quarters since. The position peaked at $488K in Q1 2022. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Anfield Capital Management held 85 shares of AbbVie worth $18.5K as of Q1 2026.
Anfield Capital Management left its AbbVie share count unchanged in Q1 2026.
AbbVie made up 0.01% of Anfield Capital Management's portfolio in Q1 2026, its #350 holding.
Anfield Capital Management first reported a position in AbbVie in Q4 2019 and has held it in 14 quarters since.
Anfield Capital Management's AbbVie position peaked at $488K in Q1 2022.
4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Anfield Capital Management's 13F filing for Q1 2026, filed 12 May 2026.